Since more than 50% of all tumors and 80% of metastatic tumors have mutations in p53 [1], our observations provide the exciting possibility that PG may be a potential therapeutic target for cancers with non-functional mutant p53s. The gene discussed is TP53; the disease is metastatic neoplasm.